These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 12845

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inhibition of bovine factor IXa and factor Xabeta by antithrombin III.
    Kurachi K, Fujikawa K, Schmer G, Davie EW.
    Biochemistry; 1976 Jan 27; 15(2):373-7. PubMed ID: 1247523
    [Abstract] [Full Text] [Related]

  • 4. Potentially thrombogenic materials in factor IX concentrates.
    Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL.
    Thromb Diath Haemorrh; 1975 Jun 30; 33(3):617-31. PubMed ID: 1154317
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo correlation of clotting protease activity: effect of heparin.
    Gitel SN, Stephenson RC, Wessler S.
    Proc Natl Acad Sci U S A; 1977 Jul 30; 74(7):3028-32. PubMed ID: 268650
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW, Abildgaard C, Shitanishi KT, Harrison J, Gendler S, Heldebrant CM.
    J Lab Clin Med; 1993 Mar 30; 121(3):394-405. PubMed ID: 8445288
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Activated clotting factors in factor IX concentrates.
    Hultin MB.
    Blood; 1979 Nov 30; 54(5):1028-38. PubMed ID: 497395
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation.
    Fischer AM, Barrowcliffe TW, Thomas DP.
    Thromb Haemost; 1982 Apr 30; 47(2):104-8. PubMed ID: 6179182
    [Abstract] [Full Text] [Related]

  • 14. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
    Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J.
    Thromb Res; 1987 Apr 15; 46(2):187-98. PubMed ID: 3603420
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Assessment of potential thrombogenicity of coagulation factor IX concentrates in an in vitro model of human thrombogenesis.
    Galan AM, Reverter JC, Bozzo J, Hernandez MR, Escolar G, Aznar-Salatti J.
    Thromb Res; 1999 Dec 01; 96(5):383-9. PubMed ID: 10605953
    [Abstract] [Full Text] [Related]

  • 18. Activation of factor X and prothrombin in antithrombin-III depleted plasma: the effects of heparin.
    Ofosu FA, Blajchman MA, Modi G, Cerskus AL, Hirsh J.
    Thromb Res; 1999 Dec 01; 23(4-5):331-45. PubMed ID: 7324001
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.